Factors involved in the generation of memory CD8+ T cells in patients with X-linked lymphoproliferative disease (XLP)

Clinical and Experimental Immunology

Volumn 147, Issue 3, 2007, Pages 456-464

  Belmonte, L ^a   Parodi, C ^a   Bare P ^a   Malbran A ^b   Ruibal Ares, B ^a   De Bracco, María M De E ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

Author keywords

CD8 effector memory; CD8 memory cells; Epstein Barr virus; XLP

Indexed keywords

ACICLOVIR; CD27 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD57 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN G; L SELECTIN; PERFORIN; RITUXIMAB; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CD8+ T LYMPHOCYTE; CELL THERAPY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE MUTATION; HUMAN; LYMPHOCYTE DIFFERENTIATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MEMORY T LYMPHOCYTE; MONONUCLEOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; T LYMPHOCYTE; VIRUS INFECTION; VIRUS LOAD; X CHROMOSOME LINKED DISORDER;

ADULT; ANTIGENS, CD27; ANTIGENS, CD28; ANTIGENS, CD70; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD, PRESCHOOL; GENETIC DISEASES, X-LINKED; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INFECTIOUS MONONUCLEOSIS; INTERFERON TYPE II; LYMPHOPROLIFERATIVE DISORDERS; MALE; VIRAL LOAD;

EID: 33846811386     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03300.x     Document Type: Article

References (28)

1. Nichols KE, Harkin DP, Levitz S et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA 1998; 95:13765-70.
2. Morra M, Howie D, Grande MS et al. X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu Rev Immunol 2001; 19:657-82.
3. Czar MJ, Kersh EN, Mijares LA et al. Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci USA 2001; 98:7449-54.
4. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus associated diseases. Annu Rev Microbiol 2000; 54:19-48.
5. Bollard CM, Savoldo B, Rooney CM, Heslop HE. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Hematol 2003; 110:139-48.
6. Appay V, Dunbar PR, Callan M et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Med 2002; 8:379-85.
7. Betts MR, Price DA, Brenchley JM et al. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol 2004; 172:6407-17.
8. Gamadia LE, van Leewen EMM, Remmerswaal EBM et al. The size and phenotype of virus-specific T cell populations is determined by repetitive antigenic stimulation and environmental cytokines. J Immunol 2004; 172:6107-14.
9. Matter M, Mumprecht S, Pinschewer DD et al. Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL. Eur J Immunol 2005; 35:3229-39.
10. Milone MC, Tsai DE, Hodinka RL et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell directed therapy. Blood 2005; 105:994-6.
11. Malbrán A, Belmonte L, Ruibal-Ares B et al. Loss of circulating CD27+ memory B cells and CCR4+ T cells in association with elevated Epstein-Barr virus (EBV) loads in XLP patients surviving primary EBV infection. Blood 2004; 103:1625-31.
12. Lanzavecchia A, Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000; 290:92-7.
13. Piriou ER, van Dort K, Weel JF et al. Detailed kinetics of EBV-specific CD4+ and CD8+ T cells during primary EBV infection in a kidney transplant patient. Clin Immunol 2006; 119:16-20.
14. Brenchley JM, Karandikar NJ, Betts MR et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003; 101:2711-20.
15. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4:25-36.
16. Masopust D, Kaech SM, Wherry EJ, Ahmed R. The role of programming in memory T-cell development. Curr Opinion Immunol 2004; 16:217-25.
17. Wherry EJ, Teichgräber V, Becker TC et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol 2003; 4:225-38.
18. Callan MF, Steven N, Krausa P et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med 1996; 2:906-11.
19. Akhbar AN, Terry L, Timms A, Beverley PC, Janossy G. Loss of CD45R and gain of UCHLI reactivity is a feature of primed T cells. J Immunol 1988; 140:2171-8.
20. Faint JM, Annels NE, Curnow SJ et al. Memory T cells constitute a subset of the human CD8+ CD45RA+ pool with distinct phenotypic and migratory characteristics. J Immunol 2001; 167:212-20.
21. Ma CS, Hare NJ, Nichols KE et al. Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells. J Clin Invest 2005; 115:1049-59.
22. Dunne PJ, Faint JM, Gudgeon NH et al. Epstein-Barr virus-specific CD8+ T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood 2002; 100:933-40.
23. Plunkett FJ, Franzese O, Belaramani LL et al. The impact of telomere erosion on memory CD8+ T cells in patients with X-linked lymphoproliferative syndrome. Mech Ageing Dev 2005; 126:855-65.
24. Piriou E, Jansen CA, Dort K et al. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy. J Immunol 2005; 175:2010-7.
25. Kimura H, Hoshino Y, Kanegane H et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98:280-6.
26. Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71:1234-43.
27. Thorley-Lawson DA, Gross A. Persistence of Epstein-Barr virus and origins of associated lymphomas. N Engl J Med 2004; 350:1328-37.
28. Piriou E, van Dort K, Nanlohy NM, Miedema F, van Oers MH, van Baarle D. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. J Immunol 2004; 172:6931-7.